NMDA Receptor Antagonist
Memantine for Cognitive Impairment in SLE
This trial is testing memantine, a drug that blocks certain brain receptors, in people with Systemic Lupus Erythematosus (SLE) who have a specific genetic variant. The goal is to see if memantine can safely and effectively reduce cognitive symptoms in these patients. Memantine is used to treat memory and thinking problems and has been investigated for similar issues in SLE patients.
Mucolytic Agent
N-acetylcysteine for Lupus
This trial is a phase II study to test the safety and efficacy of N-acetyl cysteine (NAC) in treating systemic lupus erythematosus (SLE). SLE is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. This study will have two groups of 105 subjects each, with one group continuing the tolerated dosage of NAC and the other group switched to placebo capsules. The study will last 13 months with seven study visits per subject. Each subject will donate approximately 100 ml of blood
Popular Filters
Trials for Lupus Patients
Monoclonal Antibodies
PF-06823859 for Systemic Lupus Erythematosus
This trial is researching if a drug, PF-06823859, is safe and effective for adults with CLE or SLE and skin symptoms. 48 participants will receive active study medicine or placebo for 65 weeks of study.
Mobile App Intervention for Childhood-Onset Lupus
This trial aims to see if a custom mobile app can help young people with lupus stay engaged in their medical care and manage depression. The study focuses on adolescents and young adults from the Bronx, ages 15-24. The app offers personalized support to help them keep up with health appointments and improve their mood.
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Trials for SLE Patients
Monoclonal Antibodies
PF-06823859 for Systemic Lupus Erythematosus
This trial is researching if a drug, PF-06823859, is safe and effective for adults with CLE or SLE and skin symptoms. 48 participants will receive active study medicine or placebo for 65 weeks of study.
Mobile App Intervention for Childhood-Onset Lupus
This trial aims to see if a custom mobile app can help young people with lupus stay engaged in their medical care and manage depression. The study focuses on adolescents and young adults from the Bronx, ages 15-24. The app offers personalized support to help them keep up with health appointments and improve their mood.
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Trials for ANA Positive Patients
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
Monoclonal Antibodies
Belimumab for Lupus
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
Monoclonal Antibodies
Mosunetuzumab for Lupus
This trial is testing a new medication called mosunetuzumab to see if it is safe and effective for people with systemic lupus erythematosus (SLE). The medication aims to help the immune system target harmful cells, which may help reduce the symptoms of SLE.
Monoclonal Antibodies
Obinutuzumab for Lupus
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Afimetoran for Lupus
This trial is testing a new medication called Afimetoran to help people with active Systemic Lupus Erythematosus (SLE). The goal is to see if it can safely reduce symptoms by calming down the immune system. The study will also provide data on its effectiveness and safety over time.
Trials for Anti-dsDNA Positive Patients
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
Monoclonal Antibodies
Belimumab for Lupus
This trial is testing a medication called belimumab, given as an injection under the skin, in children with lupus. The goal is to see if it is safe and effective by calming down their overactive immune systems. Belimumab is approved for the treatment of lupus in adults with moderate disease activity.
Monoclonal Antibodies
Mosunetuzumab for Lupus
This trial is testing a new medication called mosunetuzumab to see if it is safe and effective for people with systemic lupus erythematosus (SLE). The medication aims to help the immune system target harmful cells, which may help reduce the symptoms of SLE.
Monoclonal Antibodies
Obinutuzumab for Lupus
This trial is testing a medication called obinutuzumab in people with active lupus who have specific antibodies in their blood. These patients are already on standard treatments but need more help. The medication works by reducing harmful immune cells that cause inflammation and damage.
Phase 3 Trials
Cenerimod for Systemic Lupus Erythematosus
This trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing a new drug for Lupus called BIIB059. The goal is to see if it is effective in reducing disease activity, and if it has any other benefits compared to placebo. There are many secondary objectives to this study, including assessing the safety and immunogenicity of the drug.
Anti-malarial drug
Stopping Hydroxychloroquine for Lupus
This trial is testing if older lupus patients can safely stop taking Hydroxychloroquine, a drug that reduces lupus symptoms but can harm the eyes over time. The study focuses on patients aged 60 and above who have stable disease. Researchers will monitor these patients for an extended period to see if their condition remains stable without the drug.
Monoclonal Antibodies
Litifilimab for Lupus
This trial is testing litifilimab, a medication for people with active systemic lupus erythematosus (SLE). It aims to see if the drug can safely reduce the immune system's attack on the body, helping to manage symptoms and prevent organ damage. Litifilimab has shown promise in reducing the number of swollen and tender joints in SLE patients.
Trials With No Placebo
Mobile App Intervention for Childhood-Onset Lupus
This trial aims to see if a custom mobile app can help young people with lupus stay engaged in their medical care and manage depression. The study focuses on adolescents and young adults from the Bronx, ages 15-24. The app offers personalized support to help them keep up with health appointments and improve their mood.
Behavioral Intervention
Chronic Disease Self-Management Program for Systemic Lupus Erythematosus
This trial examines if a health education program can improve health and reduce healthcare use in African American women with lupus. The program involves regular sessions that teach practical skills for managing health problems. Researchers want to see if this helps these women better manage their condition. This community-based education program is designed to help participants gain confidence and skills to better manage their chronic conditions; it has been implemented worldwide.
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
View More Related Trials
Frequently Asked Questions
Introduction to systemic lupus erythematosus
What are the top hospitals conducting systemic lupus erythematosus research?
In the realm of systemic lupus erythematosus (SLE) clinical trials, top hospitals across the United States are making significant strides in understanding and treating this complex autoimmune disease. The Oklahoma Medical Research Foundation, located in Oklahoma City, takes a leading position with five ongoing SLE trials and an impressive history of 41 total trials since their first recorded investigation in 1995. Meanwhile, SUNY Upstate Medical University in Syracuse is also actively contributing to SLE research through its current participation in five clinical trials and a cumulative tally of 12 past studies dating back to their initial trial in 2008.
Notably, Tampa's reputable research site has emerged as another important player on this front, conducting four active SLE trials while having previously contributed to twelve investigations since their first recorded trial in 2007. Similarly engaged is a notable research site based out of Charlotte, which currently hosts four ongoing SLE trials and has conducted thirteen total studies since commencing their inaugural investigation into this disease's nature and potential treatments backin2008.
It is worth mentioning that NYU Langone Health from New york City may have fewer active projects than some other institutions on this list with only three current systemic lupus erythematosus clinical trials; however, they represent the cutting edge by initiating their very first study on the condition as recently as2023.
These remarkable efforts signify a collective commitment among these esteemed medical centers to improve the lives of individuals grappling with systemic lupus erythematosus. Through rigorous scientific exploration and innovative treatment approaches emerging from these clinical trials across diverse locations throughout America - ranging from bustling cities like New York to dynamic regions such as Oklahoma - researchers are dedicatedly working towards advancing our understanding of SLE alongside developing effective therapies for those affected by it worldwide
Which are the best cities for systemic lupus erythematosus clinical trials?
When it comes to systemic lupus erythematosus clinical trials, several cities have emerged as leading hubs for research and development. New york City, with its 20 active trials, explores a wide range of treatments such as Hydroxychloroquine (HCQ), Administration of CC-97540, and Arm 1: Deucravacitinib. Miami, Florida also boasts 20 ongoing studies focused on innovative approaches like Cenerimod 4 mg, ALPN-101, and GLPG3667. Additionally, Charlotte in North carolina offers 19 active trials examining treatment options including Obinutuzumab and BIIB059 Low Dose. These cities provide individuals with systemic lupus erythematosus access to cutting-edge clinical trials that may lead to improved care and better outcomes.
Which are the top treatments for systemic lupus erythematosus being explored in clinical trials?
Clinical trials for systemic lupus erythematosus are pushing boundaries to discover effective treatments. At the forefront is Cenerimod 4 mg, currently being explored in two active trials and making its debut in 2018 with one all-time trial dedicated to this condition. This promising treatment shows great potential in improving outcomes for patients battling systemic lupus erythematosus. As research progresses, there is hope that these clinical trials will bring us closer to finding more innovative therapies and ultimately providing relief for those affected by this complex autoimmune disease.
What are the most recent clinical trials for systemic lupus erythematosus?
Promising developments in the field of systemic lupus erythematosus (SLE) research are bringing hope to those affected by this challenging autoimmune disease. Recent clinical trials have introduced innovative approaches and potential treatments for SLE. These include Imvotamab, a Phase 1 trial exploring dose escalation for SLE patients, Study 3 which investigates the efficacy of Upadacitinib in treating SLE as part of its Phase 3 study, CC-97540 administration during a Phase 1 trial, Group 1's participation in a Phase 2 study focusing on SLE treatment options, and finally GLPG3667's examination through a Phase 2 trial specifically designed for individuals with SLE. With these advancements underway, there is renewed optimism that improved therapies will soon be available to enhance the lives of those living with SLE.
What systemic lupus erythematosus clinical trials were recently completed?
Several recent clinical trials have shed light on potential treatments for systemic lupus erythematosus (SLE), offering hope to those affected by this complex autoimmune disease. Notably, in February 2022, Daiichi Sankyo completed a trial investigating DS-7011a's efficacy as a therapy for SLE. Preceding this, Viela Bio concluded their trial of VIB7734 in June 2021 and Sanofi wrapped up their SAR443122 study in April 2021. These advancements follow prior breakthroughs such as Eli Lilly and Company's completion of the LY3471851 trial in August 2020 and Amgen's Rozibafusp Alfa trial concluded in February 2020. The ongoing pursuit of effective therapies reflects the commitment of researchers to better manage SLE and enhance patients' quality of life.